secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001493152-24-033144
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LIXTE reports Roche-backed trial, new CMO, and SCLC trial termination
---------------------------------------------------------------------

- New clinical trial with Netherlands Cancer Institute, supported by Roche, testing LB-100 + atezolizumab in metastatic colorectal cancer.
- Dr. Jan Schellens appointed Chief Medical Officer effective Aug 1, 2024; 25+ years oncology drug development experience.
- Preclinical data in EMBO Reports shows LB-100 can turn immunologically 'cold' tumors 'hot', enhancing immunotherapy benefit.
- Small cell lung cancer trial at City of Hope terminated due to limited patient accrual; exploring alternative sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224033144/0001493152-24-033144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224033144/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-033144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer